In the Field - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

In the Field

Pharmaceutical Technology


"CIS markets have huge potential and the eyes of multinational pharmaceutical companies are already being directed toward them," she adds. "Currently, India is the third largest exporter of drugs and pharmaceuticals to Russia.

"The CEE is also a fast-growing generics market itself with consumption of pharmaceuticals still being much lower than in Western Europe," she explains. "Thus Indian companies, like other foreign companies, are interested in supplying that market as well."

Indian companies could establish a large manufacturing presence in Europe, perhaps ultimately similar in size to that set up by US pharmaceutical producers in Europe in the 1960s and 1970s. Unlike their US counterparts a few decades ago, however, multinational Indian companies will not have to restrict themselves to Western Europe but will be able to spread across the entire continent.

Sean Milmo is a freelance writer based in Essex, United Kingdom.

World Briefs

ASIA & THE PACIFIC


WHERE IS THAT?
After a negative year in the news, China has finally agreed to improve the safety of its drug and food exports. Li Changjiang, minister of the General Administration of Quality Supervision, Inspection, and Quarantine (AQSIQ) of the People's Republic of China, and US Health and Human Services Secretary Mike Leavitt signed two Memoranda of Agreement (MoA) on Dec. 11 in Beijing, to promote information-sharing, and ensure safety and compliance.• Hikal (Mumbai, India) signed a contract manufacturing agreement with Pfizer (New York) in which Hikal will supply active pharmaceutical ingredients. • WuXi PharmaTech (Shanghai) signed a definitive agreement to acquire AppTec Laboratory Services (St. Paul, Minnesota). The transaction totals approximately $151 million with the additional assumption of AppTec debt totaling approximately $11.7 million.

EUROPE & MIDDLE EAST


2008 Forecast
Novartis (Basel, Switzerland) is launching a new initiative, called "Forward," to enhance productivity by streamlining the organization and redesigning the way it operates. "Forward" will include 2008 and 2009 initiatives estimated to bring in annual pretax cost savings of $1.6 billion in 2010, as well as the reduction of approximately 2500 full-time positions (2.5% of group total) worldwide. • Novozymes ( Bagsvaerd, Denmark) and Millipore (Billerica, MA) announced an agreement to develop, market, and sell new, animal-free, cell-culture supplements for biopharmaceutical manufacturing. The alliance will initially focus on developing recombinant human albumin and recombinant human transferrin. • La-Pha-Pack (Langerwehe, Germany), a manufacturer and provider of chromatography consumables and related products, was acquired by Thermo Fisher Scientific (Waltham, MA) and will be integrated into Thermo's laboratory consumables business. • DSM Pharma Chemicals (Parsippany, NJ), a business unit of DSM Pharmaceutical Products, entered into an enzyme supply agreement with the German company IEP(Wiesbaden) to enable scale-up of chiral alcohol manufacturing based on IEP enzymes. • sanofi-aventis (Paris) ended its participation in the development of IDM Pharma's (Irvine, CA) "Uvidem," an investigational therapy for the treating melanoma. As a result, IDM plans to restructure and reduce its workforce in the first quarter of 2008. • Biotechnology company Crucell (Lieden, The Netherlands) signed a collaboration and commercialization agreement with sanofi pasteur, the vaccines division of sanofi-aventis (Paris), for Crucell's rabies monoclonal antibodies. • Pharmaterials ( Reading, United Kingdom), a preformulation and formulation development company, was acquired by Pharmaceutics International (Baltimore), a manufacture of solid and semi-solid dosage forms.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here